Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures

29 Sept 2022

Abstract excerpt

Since 2010, significant progress has been made in the treatment of metastatic castrate resistant prostate cancer (mCRPC). While these advancements have improved survival, mCRPC remains a lethal disease, with a precision medicine framework that is lagging behind compared to other cancers. Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) studies in prostate cancer (PCa) have focused primarily on the homologous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36230674
DOI: 10.3390/cancers14194751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesPMID 36230674Read ↗

Development of PARP inhibitors in advanced prostate cancerSemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read ↗

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

Changing the History of Prostate Cancer with New Targeted TherapiesSemantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer.Semantic proximity Read ↗

Targeting DNA RepairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.